Niacin (Vitamin B3) Toxicity: Liver Damage

Liver Damage — scientific infographic poster

At the very high doses once used to lower cholesterol — not the tiny amounts found in food — niacin (vitamin B3) can injure the liver. The damage ranges from a quiet rise in liver enzymes on a blood test to, rarely, full-blown hepatitis and even liver failure. The single most important fact is this: the harm is far more likely with sustained-, extended-, or timed-release niacin than with the plain immediate-release form, and the classic disaster is a patient who switches from one to the other at the same milligram dose, not realizing they are not interchangeable. This is a real, well-documented side effect of high-dose niacin therapy — it is not something the niacin in your dinner or a basic B-complex will do. This page explains how the injury feels, why the slow-release pills are riskier, the many other things that raise liver enzymes, how it is found and reversed, and the warning signs of serious liver injury.


Table of Contents

  1. What Niacin Liver Injury Feels Like
  2. The Mechanism: Why Slow-Release Niacin Strains the Liver
  3. Honesty: Raised Liver Enzymes Have Many Causes
  4. Clues That Point to Niacin
  5. Who Gets It and How Much It Takes
  6. Getting Checked
  7. How Niacin Liver Injury Is Treated
  8. When to Seek Care / Red Flags
  9. Key Research Papers
  10. Connections
  11. Featured Videos

What Niacin Liver Injury Feels Like

The most unsettling thing about niacin liver injury is how often it begins with no feeling at all. In the early stage there is usually nothing to notice: the only sign is a rise in liver enzymes on a routine blood test, picked up precisely because doctors know to watch for it in anyone taking high-dose niacin. Many people never progress beyond this silent, reversible stage. So the absence of symptoms is no guarantee the liver is unbothered — which is exactly why blood monitoring, not how you feel, is the safeguard.

When symptoms do appear, they tend to arrive in a recognizable sequence as the injury deepens:

A particular pattern is worth naming because it has tripped up so many people: symptoms that begin within days to a few weeks after switching to, or starting, a sustained-release niacin product — especially after changing from the immediate-release form to a slow-release one at the same dose. That timing is one of the strongest clues that the liver, not a stomach virus, is the problem.

This injury is distinct from the other things high-dose niacin commonly does. The intense warmth and redness of niacin flushing is harmless and almost universal; the effects of niacin on blood sugar and uric acid (gout) are metabolic, not hepatic. Liver injury is the one that can become dangerous quietly, which is why it earns its own page.

Back to Table of Contents

The Mechanism: Why Slow-Release Niacin Strains the Liver

To understand why niacin can hurt the liver — and why the slow-release versions are the dangerous ones — it helps to know that the body handles niacin by two different chemical routes, and that the form of the pill decides which route dominates.

Once absorbed, niacin (nicotinic acid) is cleared by the liver along two pathways that work like a fast lane and a slow lane:

Here is the crux. When you take immediate-release niacin, a large dose floods the body all at once. The fast conjugation lane handles the bulk of it and the niacin is gone quickly — you get a strong flush, but relatively little is pushed down the toxic slow lane. When you take a sustained- or extended-release product, the same milligram dose is fed into the body slowly over many hours. That trickle keeps the fast lane from ever being the main route; instead, a much larger share of the niacin is steered into the low-capacity amidation pathway — the one associated with liver injury. The slow drip trades less flushing for more hepatic stress.

An analogy. Picture two doors out of a crowded room: a wide main exit (the fast lane) and a narrow side door (the slow lane). Immediate-release niacin is like opening the main exit and letting everyone rush out at once — noisy and dramatic (the flush), but the room clears fast and few people are forced through the narrow door. Sustained-release niacin keeps the main exit mostly shut and lets people leave only a trickle at a time, so a far larger fraction ends up squeezing through the narrow side door — quiet, but it overworks that fragile passage. Inside liver cells, that “overworked narrow passage” shows up as stressed, injured hepatocytes that leak their enzymes into the blood and, if pushed far enough, begin to die.

This is not a fringe theory; it is the explanation behind one of the most important findings in the niacin literature. In a randomized double-blind comparison of 46 adults, 12 of the 23 people (52%) given sustained-release niacin developed liver toxicity, and none of the 23 given immediate-release niacin did; the slow-release form lowered low-density lipoprotein (LDL) cholesterol more at 1500 mg a day and above, and the authors concluded that it is hepatotoxic and that its use should be restricted (McKenney 1994). The doses were raised step by step from 500 to 3000 mg a day, six weeks at each step. Eighteen of the 23 people (78%) on the slow-release form dropped out before reaching 3000 mg, most often because of stomach and bowel symptoms, tiredness and rising liver enzymes; 9 of the 23 (39%) on the immediate-release form dropped out, most often because of flushing and other blood-vessel symptoms, tiredness and darkened skin patches (acanthosis nigricans). The deadliest real-world scenario follows directly: a person tolerating, say, immediate-release niacin substitutes the same number of milligrams of a sustained-release product — assuming they are equivalent — and unknowingly redirects that dose down the toxic pathway. A published case report describes exactly this substitution: a patient developed severe liver dysfunction, with low body temperature, low blood pressure and acid build-up in the blood, two days after a sustained-release product replaced a crystalline (immediate-release) niacin the patient had tolerated well (Dalton 1992). In another report, three patients who had developed hepatitis on sustained-release niacin were later given equal or higher doses of crystalline niacin with no return of liver damage (Henkin 1990) — three cases only.

Back to Table of Contents

Honesty: Raised Liver Enzymes Have Many Causes

It would be misleading to suggest that abnormal liver tests or right-sided belly pain in a niacin user must be the niacin. Elevated liver enzymes are one of the most common abnormal blood results in all of medicine, and the great majority of the time the cause is something other than a vitamin. Honesty here matters, because chasing the wrong cause — or blaming niacin and missing a more serious disease — can be harmful. Among the far more frequent reasons liver enzymes climb:

The honest bottom line: niacin can injure the liver, and in someone on high-dose slow-release niacin it deserves serious consideration — but it is one cause among many. A good evaluation does not assume; it weighs the dose and form of niacin against the person's drinking, weight, other medicines, and risk for viral and other liver disease. The big-picture view of liver disease is on the Liver Disease page.

Back to Table of Contents

Clues That Point to Niacin

Given how many things raise liver enzymes, what tilts the picture toward niacin? A few features make the vitamin a much more likely culprit:

None of these proves it on its own, and a clinician will still rule out the common alternatives above. But the combination of a high-dose slow-release product, a recent switch, and enzymes that settle after stopping is a compelling case for niacin.

Back to Table of Contents

Who Gets It and How Much It Takes

Niacin liver injury is overwhelmingly a story about dose and formulation, with a few personal factors layered on top.

A note on niacin's place in treatment today: large cardiovascular outcome trials — AIM-HIGH and HPS2-THRIVE — found that adding niacin to good statin therapy did not reduce heart attacks or strokes and added side effects, which is why niacin is now used much less often for cholesterol than it once was. It still has selective uses, but its decline means fewer people are exposed to its hepatic risk than in past decades.

Liver failure from niacin is not only a cholesterol-clinic story. A 2024 report from an intensive care unit in Perth, Australia describes acute fulminant liver failure in a 24-year-old woman caused by overdosing on vitamin B3 from dietary supplements (Duffy 2024).

Back to Table of Contents

Getting Checked

Finding and confirming niacin liver injury rests on blood tests, an honest medication-and-supplement history, and ruling out the common alternatives — not on imaging or anything invasive in most cases.

The core test is a panel of liver function tests (often part of a comprehensive metabolic panel). The key numbers are the transaminases alanine aminotransferase (ALT) and aspartate aminotransferase, which leak from injured liver cells; alkaline phosphatase, which points to the bile ducts; and bilirubin, the pigment that causes jaundice when it builds up. A drug-injury pattern from niacin is usually hepatocellular — alanine aminotransferase and aspartate aminotransferase rise disproportionately to alkaline phosphatase — and a rising bilirubin signals more serious injury. Doctors also check the international normalized ratio (INR) (a clotting measure), because a liver too injured to make clotting proteins is a sign of severe disease.

This is one of the few situations in which monitoring is built into treatment from the start. Standard practice for anyone on high-dose niacin is to check liver enzymes before starting and periodically afterward — particularly after any dose increase or change of product — so that a rise is caught at the silent, reversible stage rather than after jaundice appears. If enzymes climb, the niacin is typically held and the tests repeated to see whether they fall (the dechallenge described earlier). Alongside this, a clinician will take a careful history of alcohol, every other prescription and over-the-counter drug and supplement, and risk factors for viral hepatitis, and will usually order hepatitis screening and sometimes a liver ultrasound to exclude fatty liver, gallstones, or bile-duct obstruction before settling on niacin as the cause.

Back to Table of Contents

How Niacin Liver Injury Is Treated

The good news is that, caught in time, niacin liver injury is usually reversible, and the central treatment is straightforward: stop the niacin.

For people who take niacin and tolerate it, the facts that matter most are these: slow-release and immediate-release niacin are not interchangeable at the same milligram dose; liver injury is silent at first and is found by a liver-enzyme blood test; alcohol adds to the liver's load; and new fatigue, nausea, belly pain or any yellowing are the early signs of liver injury.

Back to Table of Contents

When to Seek Care / Red Flags

Because the early stage is silent and the serious stage can move quickly, certain signs in anyone taking high-dose niacin are signs of liver injury that hospitals treat as urgent:

The facts behind the monitoring: the Tolerable Upper Intake Level for supplemental niacin is 35 mg a day for adults, while cholesterol-lowering doses are 1–3 grams a day. At those doses liver injury can be present with no symptoms at all, and only a liver-enzyme blood test (alanine aminotransferase and aspartate aminotransferase) shows it before symptoms start.

Back to Table of Contents

Key Research Papers

  1. McKenney JM, Proctor JD, Harris S, Chinchili VM (1994). A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients. JAMA;271(9):672-677. — DOI: 10.1001/jama.1994.03510330050033. — doi:10.1001/jama.1994.03510330050033
  2. Henkin Y, Johnson KC, Segrest JP (1990). Rechallenge With Crystalline Niacin After Drug-Induced Hepatitis From Sustained-Release Niacin. JAMA;264(2):241-243. — DOI: 10.1001/jama.1990.03450020093033. — doi:10.1001/jama.1990.03450020093033
  3. Etchason JA, Miller TD, Squires RW, et al. (1991). Niacin-Induced Hepatitis: A Potential Side Effect With Low-Dose Time-Release Niacin. Mayo Clinic Proceedings;66(1):23-28. — DOI: 10.1016/s0025-6196(12)61171-9. — doi:10.1016/s0025-6196(12)61171-9
  4. Dalton TA, Berry RS (1992). Hepatotoxicity associated with sustained-release niacin. The American Journal of Medicine;93(1):102-104. — DOI: 10.1016/0002-9343(92)90689-9. — doi:10.1016/0002-9343(92)90689-9
  5. Guyton JR, Simmons PD (2009). Flushing and other dermatologic adverse events associated with extended-release niacin therapy. Journal of Clinical Lipidology;3(2):101-108. — DOI: 10.1016/j.jacl.2009.02.003. — doi:10.1016/j.jacl.2009.02.003
  6. Kei A, Elisaf MS (2012). Nicotinic acid: clinical considerations. Expert Opinion on Drug Safety;11(4):551-564. — DOI: 10.1517/14740338.2012.682981. — doi:10.1517/14740338.2012.682981
  7. Morgan JM, Capuzzi DM, Guyton JR (1998). A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. The American Journal of Cardiology;82(12A):29U-34U. — DOI: 10.1016/s0002-9149(98)00732-2. — doi:10.1016/s0002-9149(98)00732-2
  8. AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, et al. (2011). Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine;365(24):2255-2267. — DOI: 10.1056/nejmoa1107579. — doi:10.1056/nejmoa1107579
  9. HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, et al. (2014). Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine;371(3):203-212. — DOI: 10.1056/nejmoa1300955. — doi:10.1056/nejmoa1300955
  10. Boden WE, Probstfield JL, Anderson T, et al. (2011). The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design (AIM-HIGH). American Heart Journal;161(3):471-477.e2. — DOI: 10.1016/j.ahj.2010.11.017. — doi:10.1016/j.ahj.2010.11.017
  11. Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ (2013). LiverTox: A website on drug-induced liver injury. Hepatology;57(3):873-874. — DOI: 10.1002/hep.26175. — doi:10.1002/hep.26175
  12. Duffy M, Zhang G, Ariyawansa C, Anstey MH (2024). Niacin (Vitamin B3)-Induced Acute Fulminant Hepatic Failure in a 24-Year-Old Female. Cureus;16(9):e69518. — DOI: 10.7759/cureus.69518. — PubMed PMID: 39416578

PubMed Topic Searches

  1. PubMed: Niacin hepatotoxicity and sustained-release formulations
  2. PubMed: Niacin-induced hepatitis and liver injury
  3. PubMed: Sustained-release vs immediate-release niacin toxicity
  4. PubMed: Niacin and fulminant hepatic failure
  5. PubMed: High-dose niacin and liver-function monitoring

Back to Table of Contents

Connections

Back to Table of Contents